自体与异体脂肪再生细胞联合微脂肪治疗复杂性肛瘘的双盲随机I-II期试验
丹麦奥登塞大学医院开展双盲随机非劣效I-II期试验,纳入75例复杂性隐源性肛瘘成人患者,比较自体ADRCs与异体ADRC001联合微脂肪注射及微创清创的疗效。主要结局为12个月临床愈合率,次要结局包括生活质量、肛门控便功能、复发危险因素及影像学愈合。
要点
- 纳入≥18岁复杂性肛瘘(高位经括约肌或括约肌上,累及>30%肛门括约肌)成人患者。
- 主要结局为12个月临床愈合率;次要结局含SF-36、Wexner评分、MRI评估愈合及免疫应答比较。
核心结论
- 该试验旨在评估异体ADRCs联合微脂肪是否可作为自体ADRCs联合微脂肪的可行替代方案。
- 试验预期为复杂性肛瘘提供微创治疗证据,可能缩短恢复时间并避免括约肌损伤。
研究设计与样本
- 双盲、随机、干预性、非劣效I-II期临床试验,使用两种已批准的研究用药品。
- 在丹麦奥登塞大学医院外科开展,计划纳入75例复杂性肛瘘成人患者,1:1随机分配。
主要发现
- 原文未报告试验结果,仅描述研究方案与结局指标。
关键数值与推荐
- 纳入标准:成人(≥18岁)复杂性肛瘘(高位经括约肌或括约肌上),累及超过30%肛门括约肌。
- 关键排除标准:持续化脓、简单肛瘘、肛门或直肠阴道瘘、炎症性肠病、BMI<18.5 kg/m2、青霉素或链霉素过敏、妊娠、筛查确诊梅毒/HIV/肝炎。
- 主要结局:12个月临床愈合率;次要结局包括SF-36、Wexner粪便失禁评分、MRI评估的影像学愈合及复发危险因素。
临床怎么用
- 该方案为复杂性隐源性肛瘘提供微创治疗选择,可能保留括约肌功能并加速恢复。
- 若异体ADRCs非劣效于自体ADRCs,可简化流程并提高可及性。
局限性
- 原文未报告试验结果,无法评估疗效与安全性。
- 非劣效界值、样本量计算依据及具体统计方法未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical treatment of high anal fistulas is challenging and associated with a relatively high rate of complications and failure. Stem cell therapy has shown promising results for fistulas associated with Crohn's disease but remains less studied in cryptoglandular fistulas. This clinical trial is being performed to evaluate the outcome of treating complex cryptoglandular perianal fistulas (PAFs) using minimal surgical debridement combined with either non-cultured (autologous) or cultured (allogeneic) adipose-derived regenerative cells (ADRCs). The primary outcome is the clinical healing rate after 12 months. Secondary outcomes include functional outcomes regarding quality of life and anal continence (measured by the 36-Item Short Form Health Survey [SF-36] and the Wexner Fecal Incontinence Score), risk factors for fistula recurrence, radiological healing assessed by magnetic resonance imaging, and comparison of autologous versus allogeneic ADRCs with respect to cell characterization, immune responses, and efficacy. METHODS: This is a double-blinded, randomized interventional non-inferiority, phase I-II clinical trial using two approved investigational medicinal products. The study will be conducted at the surgical department, Odense University Hospital OUH, in Odense, Denmark. Inclusion criterion is an adult patient (≥ 18 years) with complex PAF (high transsphincteric or suprasphincteric), involving more than 30% of the anal sphincter. Key exclusion criteria are ongoing suppuration, simple anal fistula, ano- or rectovaginal fistula, inflammatory bowel disease, body mass index (BMI) of < 18.5 kg/m2, known allergy to penicillin or streptomycin, pregnancy, and verified syphilis, human immunodeficiency virus (HIV), or hepatitis on screening test. The primary investigator (PI) is responsible for participants' recruitment. Eligible patients will undergo 1-day surgery, including debridement of the fistula tract and closure of the internal orifice, liposuction from the anterior abdominal wall, injection of 30-40 mL of autologous microfat around the fistula tract, and injection of 30 million stem cells (either autologous ADRCs or allogeneic ADRC001) according to randomization (1:1 allocation ratio). Patients who receive treatment will attend follow-up visits at 3, 6, and 12 months postoperatively. Serious adverse events will be reported including large abscess formation, wound dehiscence causing fecal incontinence, sepsis, major bleeding, and serious allergic reactions. The trial has been approved by the European Medicines Agency EMA and is monitored by the Good Clinical Practice (GCP) Unit at OUH. A total of 75 patients will be included. Recruitment began in October 2024, with a planned duration of 3 years. DISCUSSION: The trial intervention is designed as a minimally invasive treatment with the potential to shorten and ease recovery, enable a quicker return to daily activities and work, and avoid sphincter damage, thereby preserving function. The trial is expected to provide evidence on whether allogeneic ADRCs combined with microfat are a viable alternative to autologous ADRCs with microfat for the treatment of PAF. TRIAL REGISTRATION: Clinical Trials Information System (CTIS) EU CT 2022-502659-73-01. Registered on 18 November 2023. CLINICALTRIALS: org NCT0 6303752. Registered on 25 February 2024.
引用
- Sørensen KM, Jensen CH, Möller S, et al. Repairing Peri-Anal Fistulas with regenerative cell therapeutics: study protocol for a double-blinded randomized controlled phase I-II trial from Denmark (REP-PAF). Trials. 2026. PMID: 41782164. doi:10.1186/s13063-026-09565-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。